The neuromodulation community is based on a multidisciplinary approach that is diverse in its delivery. The pedigree of clinicians that offer and employ neuromodulation in their practice vary from neurosurgeons, orthopedic spine surgeons, and anesthesiologists to neurologists and rehabilitation physicians. For the formal nonsurgical residencies, an ACGME (Accreditation Counsel of Graduate Medical Education) -accredited fellowship is necessary to become Pain Board Certified. The most common disease indications for spinal cord stimulation (SCS) include FBSS, and complex regional pain syndrome (CRPS). The literature supports that SCS can produce at least 50 % pain relief in 50–60 % of the implanted patients and reduce the use of more medications [1]. Interestingly, with the proper follow-up care, these results can be maintained [1, 2]. Very few other invasive modalities can claim this success rate. In addition to SCS there are other therapies including intrathecal drug delivery (IDD), peripheral nerve stimulation (PNS), peripheral nerve field stimulation (PNfS), as well as kyphoplasty and vertebroplasty which can be implemented into this multidisciplinary approach.

For advanced pain care therapies, it is generally accepted that a trial is performed prior to implant. There are several factors that are important in being aware of these therapies and having access to them for your patients.